University of Leicester (The) and Isogenica Limited KTP 22_23 R5
Lead Participant:
THE UNIVERSITY OF LEICESTER
Abstract
To develop a new to market drug validated in pre-clinical programmes ('virtual cancer patient') aimed at improving cancer immunotherapy.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| THE UNIVERSITY OF LEICESTER | £268,394 | £ 179,824 |
Participant |
||
| UNIVERSITY OF LEICESTER | ||
| INNOVATE UK | ||
| ISOGENICA LIMITED |
People |
ORCID iD |